Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tryptizole + Librax refers to a combination drug regimen evaluated by Fayoum University for the treatment of primary palmar hyperhidrosis. This regimen consists of amitriptyline (the active ingredient in Tryptizole), a tricyclic antidepressant, and Librax, which is a fixed-dose combination of chlordiazepoxide (a benzodiazepine) and clidinium bromide (an anticholinergic). The therapeutic rationale for this combination in hyperhidrosis relies on the potent antimuscarinic properties of both amitriptyline and clidinium bromide, which inhibit the eccrine sweat glands' response to acetylcholine. Additionally, chlordiazepoxide serves to reduce anxiety-induced sympathetic overactivity, a common trigger for palmar sweating. This specific oral combination was compared against stellate ganglion block in clinical research conducted in Egypt.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amitriptyline + chlordiazepoxide + clidinium bromide.